View in browser Latest in vitro toxicology innovation at SOT2023 in Nashville We had a fantastic time at this year’s SOT live meeting, reuniting with all our colleagues in the area of in vitro toxicology. Together with guest speakers from ExxonMobil Biomedical Sciences and The Research Institute for Fragrance Materials (RIFM), we presented the latest GARD® data on quantitative risk assessment and regulatory testing of skin sensitizers, and the potential to further broaden the GARD® applicability.  ExxonMobil Biomedical Sciences: GARD® for UVCBs and formulated lubricant products  Dr Allison Greminger of Exxon Biomedical Sciences presenting the use of the GARD®skin assay to detect dermal sensitization potential in UVCBs and formulated lubricant products.   Investigating the applicability domain of GARD® for photosensitization with RIFM Guest speaker Gretchen Ritacco presenting the potential to further broaden the applicability of the GARD® assay to assess the endpoint of photosensitization in RIFM's safety assessment program.  Avoiding high development costs for potentially hazardous chemical substances  We are very pleased that yet another global chemicals company has chosen to collaborate with us, using GARD®   skin to assess whether their new product candidates can cause allergic reactions on the skin.    Read more about the collaboration    Using in vitro data in your CE marking submission of Medical Devices Avoid animal testing and accelerate time to market Swedish Medtech company Duearity has successfully used results from in vitro assays for the endpoints of cytotoxicity, skin irritation and skin sensitization (GARD®skin Medical Device) to demonstrate the safety and performance of their medical device in their biological evaluation. Recently the company obtained CE marking under the MDR using the generated data. Duearity avoided unnecessary testing on animals and saved time to market.   Please provide me with the case study on this project GARDskin assay offers unprecedented ‘potential way forward’ to test photosensitivity, says Research Institute for Fragrance Materials, Inc. (RIFM) principal scientist To ensure product formulations are safe and effective for end users, skin care product manufacturers may soon be able to rely on the GARD®skin assay to determine if an active ingredient is a potential photoirritant to consumers' skin. Read more about our project with RIFM in this article featured in CosmeticsDesign Upcoming events 🌎 Conference: BTS Annual Congress 2023 - British Toxicology Society Birmingham, UK | April 17-19 🎧 Webinar: Recap on SenzaGen’s 2023 SOT Exhibitor Hosted Session April 26, CEST 16.00-17.00  🌎 Conference: ISID Expo | Tokyo, Japan | May 13-15 SOT 2023 recap webinar on April 26  In case you missed our Exhibitor-Hosted session at the SOT2023 Annual Meeting, we are hosting a free recap webinar on April 26th. Read more and register by using the button below.  SOT Recap Webinar April 26 – Register Here! Copyright © SenzaGen 2023 All rights reserved. SenzaGen AB | Medicon Village | 223 81 Lund, Sweden You are receiving this email because you expressed interest in SenzaGen's technology in the past. Unsubscribe here if you do not wish to receive technology updates and news from us.